Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook
Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook · Barrons.com

Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.